Pericyte depletion results in hypoxia-associated epithelial-to-mesenchymal transition and metastasis mediated by met signaling pathway.

[1]  Rakesh K. Jain,et al.  Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases , 2011, Nature Reviews Drug Discovery.

[2]  D. Hanahan,et al.  Counterbalancing angiogenic regulatory factors control the rate of cancer progression and survival in a stage-specific manner , 2011, Proceedings of the National Academy of Sciences.

[3]  W. You,et al.  VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer. , 2011, Cancer research.

[4]  W. You,et al.  Pericyte deficiencies lead to aberrant tumor vascularizaton in the brain of the NG2 null mouse. , 2010, Developmental biology.

[5]  A. Raza,et al.  Pericytes and vessel maturation during tumor angiogenesis and metastasis , 2010, American journal of hematology.

[6]  J. Meyerhardt,et al.  HIF1A overexpression is associated with poor prognosis in a cohort of 731 colorectal cancers. , 2010, The American journal of pathology.

[7]  A. Sood,et al.  Targeting pericytes with a PDGF-B aptamer in human ovarian carcinoma models , 2010, Cancer biology & therapy.

[8]  J. Griffin,et al.  Hypoxia potentiates Notch signaling in breast cancer leading to decreased E-cadherin expression and increased cell migration and invasion , 2009, British Journal of Cancer.

[9]  J. Thiery.  [Epithelial-mesenchymal transitions in cancer onset and progression]. , 2009, Bulletin de l'Academie nationale de medecine.

[10]  R. Huang,et al.  Epithelial-Mesenchymal Transitions in Development and Disease , 2009, Cell.

[11]  K. Yamaguchi,et al.  Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases. , 2009, Cancer research.

[12]  Shuang-yin Han,et al.  Hypoxia-inducible factor-1alpha induces Twist expression in tubular epithelial cells subjected to hypoxia, leading to epithelial-to-mesenchymal transition. , 2009, Kidney international.

[13]  M. Nieto,et al.  Epithelial-mesenchymal transitions: the importance of changing cell state in development and disease. , 2009, The Journal of clinical investigation.

[14]  Raghu Kalluri,et al.  EMT: when epithelial cells decide to become mesenchymal-like cells. , 2009, The Journal of clinical investigation.

[15]  Raghu Kalluri,et al.  The basics of epithelial-mesenchymal transition. , 2009, The Journal of clinical investigation.

[16]  John M L Ebos,et al.  Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. , 2009, Cancer cell.

[17]  Masahiro Inoue,et al.  Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. , 2009, Cancer cell.

[18]  P. Dore‐Duffy,et al.  Pericytes: pluripotent cells of the blood brain barrier. , 2008, Current pharmaceutical design.

[19]  Charis Eng,et al.  Direct evidence for epithelial-mesenchymal transitions in breast cancer. , 2008, Cancer research.

[20]  T. Mccauley,et al.  Sequential loss of tumor vessel pericytes and endothelial cells after inhibition of platelet-derived growth factor B by selective aptamer AX102. , 2007, Cancer research.

[21]  Liz Y. Han,et al.  Dual Targeting of Endothelial Cells and Pericytes in Antivascular Therapy for Ovarian Carcinoma , 2007, Clinical Cancer Research.

[22]  M. Westphal,et al.  Hypoxia can induce c‐Met expression in glioma cells and enhance SF/HGF‐induced cell migration , 2007, International journal of cancer.

[23]  P. Bonnier,et al.  Poor prognosis in breast carcinomas correlates with increased expression of targetable CD146 and c-Met and with proteomic basal-like phenotype. , 2007, Human pathology.

[24]  Shinji Yamazaki,et al.  An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. , 2007, Cancer research.

[25]  R. Figlin,et al.  Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. , 2007, The New England journal of medicine.

[26]  Mark W. Kieran,et al.  Identification of fibroblast heterogeneity in the tumor microenvironment , 2006, Cancer biology & therapy.

[27]  U. Ozerdem.  Targeting Pericytes Diminishes Neovascularization in Orthotopic Uveal Melanoma in Nerve/Glial Antigen 2 Proteoglycan Knockout Mouse , 2006, Ophthalmic Research.

[28]  K. Nakashiro,et al.  Hypoxia enhances c-Met/HGF receptor expression and signaling by activating HIF-1alpha in human salivary gland cancer cells. , 2006, Oral oncology.

[29]  J. Pouysségur,et al.  Hypoxia signalling in cancer and approaches to enforce tumour regression , 2006, Nature.

[30]  K. Neurath,et al.  Hypoxia stimulates breast carcinoma cell invasion through MT1-MMP and MMP-2 activation , 2006, Oncogene.

[31]  Quynh-Thu Le,et al.  Lysyl oxidase is essential for hypoxia-induced metastasis , 2006, Nature.

[32]  L. Akslen,et al.  Vascular proliferation is important for clinical progress of endometrial cancer. , 2006, Cancer research.

[33]  Holger Gerhardt,et al.  Pericytes limit tumor cell metastasis. , 2006, The Journal of clinical investigation.

[34]  U. Ozerdem.  Targeting of pericytes diminishes neovascularization and lymphangiogenesis in prostate cancer , 2006, The Prostate.

[35]  Weilin Zhou,et al.  Brain Endothelial Hemostasis Regulation by Pericytes , 2006, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[36]  M. Ohmichi,et al.  Up-regulation of c-met protooncogene product expression through hypoxia-inducible factor-1alpha is involved in trophoblast invasion under low-oxygen tension. , 2005, Endocrinology.

[37]  Steven Song,et al.  The role of pericytes in blood-vessel formation and maintenance. , 2005, Neuro-oncology.

[38]  A. Mori,et al.  Absence of Smooth Muscle Actin-Positive Pericyte Coverage of Tumor Vessels Correlates with Hematogenous Metastasis and Prognosis of Colorectal Cancer Patients , 2005, Oncology.

[39]  J. Joyce,et al.  Therapeutic Targeting of the Tumor Microenvironment. , 2021, Cancer discovery.

[40]  Kristian Pietras,et al.  A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  A. Harris,et al.  Differential prognostic impact of hypoxia induced and diffuse HIF-1α expression in invasive breast cancer , 2005, Journal of Clinical Pathology.

[42]  S. Ramaswamy,et al.  Twist, a Master Regulator of Morphogenesis, Plays an Essential Role in Tumor Metastasis , 2004, Cell.

[43]  Rakesh K. Jain,et al.  Vascular Normalization by Vascular Endothelial Growth Factor Receptor 2 Blockade Induces a Pressure Gradient Across the Vasculature and Improves Drug Penetration in Tumors , 2004, Cancer Research.

[44]  W. Birchmeier,et al.  Met, metastasis, motility and more , 2003, Nature Reviews Molecular Cell Biology.

[45]  G. Semenza.  Angiogenesis in ischemic and neoplastic disorders. , 2003, Annual review of medicine.

[46]  Rakesh K Jain,et al.  Molecular regulation of vessel maturation , 2003, Nature Medicine.

[47]  D. Hanahan,et al.  Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. , 2003, The Journal of clinical investigation.

[48]  P. Comoglio,et al.  Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. , 2003, Cancer cell.

[49]  P. V. van Diest,et al.  Levels of hypoxia‐inducible factor‐1α independently predict prognosis in patients with lymph node negative breast carcinoma , 2003, Cancer.

[50]  A. Harris,et al.  Hypoxia-inducible factor (HIF1A and HIF2A), angiogenesis, and chemoradiotherapy outcome of squamous cell head-and-neck cancer. , 2002, International journal of radiation oncology, biology, physics.

[51]  W. Stallcup,et al.  NG2 proteoglycan is expressed exclusively by mural cells during vascular morphogenesis , 2001, Developmental dynamics : an official publication of the American Association of Anatomists.

[52]  D. Hanahan,et al.  MMP-9 Supplied by Bone Marrow–Derived Cells Contributes to Skin Carcinogenesis , 2000, Cell.

[53]  S. Liebner,et al.  Claudin-1 and claudin-5 expression and tight junction morphology are altered in blood vessels of human glioblastoma multiforme , 2000, Acta Neuropathologica.

[54]  M. Schindl,et al.  Overexpression of hypoxia-inducible factor 1alpha is a marker for an unfavorable prognosis in early-stage invasive cervical cancer. , 2000, Cancer research.

[55]  R. Jain,et al.  Oncotic pressure in solid tumors is elevated. , 2000, Cancer research.

[56]  G M Tozer,et al.  Hypoxia modulated gene expression: angiogenesis, metastasis and therapeutic exploitation. , 2000, European journal of cancer.

[57]  H. Augustin,et al.  Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. , 2000, Cancer research.

[58]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[59]  E. Rofstad.  Microenvironment-induced cancer metastasis , 2000, International journal of radiation biology.

[60]  C. Betsholtz,et al.  Role of PDGF-B and PDGFR-beta in recruitment of vascular smooth muscle cells and pericytes during embryonic blood vessel formation in the mouse. , 1999, Development.

[61]  M. Dewhirst,et al.  Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. , 1997, International journal of radiation oncology, biology, physics.

[62]  B. Nordlinger,et al.  Overexpression and amplification of the met/HGF receptor gene during the progression of colorectal cancer. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[63]  P. Newman,et al.  The Role of PECAM‐1 in Vascular Cell Biology a , 1994, Annals of the New York Academy of Sciences.

[64]  P. Comoglio,et al.  Expression of the c-Met/HGF receptor in human melanocytic neoplasms: demonstration of the relationship to malignant melanoma tumour progression. , 1993, British Journal of Cancer.

[65]  H. Tsubouchi,et al.  The presence of scatter factor in patients with metastatic spread to the pleura. , 1992, British Journal of Cancer.

[66]  E Medico,et al.  Expression of the Met/HGF receptor in normal and neoplastic human tissues. , 1991, Oncogene.

[67]  S Ferrone,et al.  Expression of the high molecular weight melanoma-associated antigen by pericytes during angiogenesis in tumors and in healing wounds. , 1989, The American journal of pathology.

[68]  R K Jain,et al.  Transport of molecules in the tumor interstitium: a review. , 1987, Cancer research.

[69]  J. Folkman.  Tumor angiogenesis: therapeutic implications. , 1971, The New England journal of medicine.

[70]  P. Dore‐Duffy,et al.  Morphology and properties of pericytes. , 2011, Methods in molecular biology.

[71]  D. Hirst,et al.  Investigation of pericytes, hypoxia, and vascularity in bladder tumors: association with clinical outcomes. , 2008, Oncology research.

[72]  A. Bikfalvi,et al.  Tumor angiogenesis , 2020, Advances in cancer research.

[73]  Suyun Huang,et al.  Regulation of cancer metastasis by stress pathways , 2004, Clinical & Experimental Metastasis.

[74]  Juthamas Sukbuntherng,et al.  In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[75]  Adrian L. Harris,et al.  Hypoxia — a key regulatory factor in tumour growth , 2002, Nature Reviews Cancer.

[76]  W. Stallcup,et al.  NG2 proteoglycan expression by pericytes in pathological microvasculature. , 2002, Microvascular research.

[77]  T. Clark,et al.  A simple noncontact wide-angle fundus photography procedure for clinical and research use. , 2001, Retina.

[78]  J. Folkman.  Angiogenesis in cancer, vascular, rheumatoid and other disease , 1995, Nature Medicine.